https://www.fiercebiotech.com/biotech/bms-calls-it-quits-anti-tigit-and-handful-other-early-mid-stage-meds
0
0
9/14/23 at 5:57pm
Organization
FierceBiotech
Author
Max Bayer
As the TIGIT class gets closer to finally seeing clinical success, Bristol Myers Squibb is trimming one of its candidates. | As the TIGIT class gets closer to possible clinical success, Bristol Myers Squibb is trimming one of its candidates.
Create an account
or login to join the discussion